POLBF (Poolbeg Pharma) 3-Year Book Growth Rate: -31.30% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poolbeg Pharma 3-Year Book Growth Rate?

Poolbeg Pharma POLBF +0.84% 3-Year Book Growth Rate is -31.30% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 1,126 Biotechnology companies, Poolbeg Pharma ranks worse than 73.36% on this metric.

Poolbeg Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was $0.02.

During the past 12 months, Poolbeg Pharma's average Book Value per Share Growth Rate was -36.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was -31.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Poolbeg Pharma was -25.00% per year. The lowest was -31.30% per year. And the median was -28.15% per year.

Poolbeg Pharma  (OTCPK:POLBF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Poolbeg Pharma 3-Year Book Growth Rate Related Terms

POLBF vs VRTX, REGN, MRNA: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, Poolbeg Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's 3-Year Book Growth Rate falls into.


Poolbeg Pharma 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of -31.30% mean?
Poolbeg Pharma (POLBF) has a 3-Year Book Growth Rate of -31.30% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #826 out of 1126 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Poolbeg Pharma's 3-Year Book Growth Rate too high?
Poolbeg Pharma's current 3-Year Book Growth Rate is -31.30%. Based on the distribution chart, Poolbeg Pharma ranks #826 out of 1126 companies in the Biotechnology industry, which is below the industry midpoint.
How does Poolbeg Pharma's 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #826 out of 1126 companies for 3-Year Book Growth Rate. This places Poolbeg Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Poolbeg Pharma and its competitors. Poolbeg Pharma's current 3-Year Book Growth Rate is -31.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current 3-Year Book Growth Rate of -31.30%. The current 3-Year Book Growth Rate is -31.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current 3-Year Book Growth Rate is -31.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.